** Shares of Monopar Therapeutics tumble ~18% to $14.65 post-market after co unveils planned equity raise ** Co announces stock offering on best effort basis; deal size not disclosed
** It plans to use net proceeds for general purposes, including R&D, clinical trial expenditures, among other uses
** Co has 3.9 mln shares outstanding for ~$70 mln market cap and ~2 mln shares of free float, per LSEG
** MNPR closed Monday's session up 5.3% at $17.83 ** On Thurs, stock surged seven-fold from $4.63 to close at $32.66 after co inked licensing deal with AstraZeneca for AZN's experimental drug being tested for Wilson disease, a rare genetic condition that causes the buildup of toxic copper levels
** Rodman & Renshaw exclusive placement agent for stock offering
(Lance Tupper is a Reuters market analyst. The views expressed are his own) ((lance.tupper@thomsonreuters.com lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。